GLIMMER: an interim subgroup analysis from an ongoing prospective study evaluating hyperspectral imaging for MGMT promoter methylation in gliomas.

ABSTRACT:

Background

MGMT promoter methylation is of importance in glioma regarding prognosis and management. Non-methylated MGMT glioblastoma patients seem to benefit more from gross total resection. MGMT status is not ultra-rapidly available in the operating room. The presents study is the first aiming to evaluate whether the novel imaging technique intraoperative hyperspectral imaging (HSI) can predict MGMT promoter methylation status in glioma patients using a novel optical scoring system.

Methods

This was a prospective subgroup analysis of 25 glioma patients enrolled in a single-center observational study. Patients underwent in-vivo HSI (spectral range: 500-1000 nm) targeting non-contrast-enhancing tumor regions during resection. Two optical parameters-tissue water index (TWI) an

SUBMITTER: Wach J 

PROVIDER: S-EPMC12628469 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature